Wird geladen...
Constraints on the Dominant Mechanism for HIV Viral Dynamics in Patients on Raltegravir
BACKGROUND: Raltegravir is the first publicly released HIV-1 integrase inhibitor. In clinical trials, patients on a raltegravir-based HAART regimen were observed to have 70% less viremia in the second phase-decay of viremia than patients on an efavirenz-based HAART regimen. Because of this accelerat...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2009
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2980788/ https://ncbi.nlm.nih.gov/pubmed/19430101 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|